Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | S100B | P04271 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | NQO1 | P15559 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30929112 | 1.00 | PDE10A (0.43) | PDE10AKDM4EPOLBS100BKMT2A | |
| SCHEMBL29891518 | 0.87 | KMO (0.43) | PDE10AKDM4EPOLBS100BMAPT | |
| SCHEMBL23411638 | 0.87 | KMO (0.43) | PDE10AKDM4EPOLBS100BMAPT | |
| SCHEMBL10465112 | 0.77 | ALDH1A1 (0.51) | KDM4EPOLBKMT2AMEN1MAPT | |
| SCHEMBL30235556 | 0.77 | ALDH1A1 (0.51) | KDM4EPOLBKMT2AMEN1MAPT | |
| SCHEMBL1319021 | 0.77 | MAPT (0.53) | KDM4EPOLBKMT2AMEN1MAPT | |
| SCHEMBL29811358 | 0.77 | MAPT (0.53) | KDM4EPOLBKMT2AMEN1MAPT | |
| SCHEMBL7983553 | 0.75 | S100B (0.44) | KDM4ES100BKMT2AMEN1MAPT | |
| SCHEMBL11645299 | 0.74 | RXFP1 (0.41) | KDM4EPOLBKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7329420 | 0.72 | ELANE (0.46) | KDM4EKMT2AMAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615454-A1 | SOS1 INHIBITORS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-09-17 | — | — | EP | disclosed |
| US-20240190868-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (HK) | 2024-06-13 | — | — | US | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
| US-8058431-B2 | Fluorescent double stranded DNA binding dyes | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2087043-B1 | NEW DS DNA BINDING FLUORESCENT DYES | ROCHE DIAGNOSTICS GMBH (DE) | 2010-08-04 | — | — | EP | disclosed |
| US-20090275037-A1 | FLUORESCENT DOUBLE STRANDED DNA BINDING DYES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2009-11-05 | — | — | US | disclosed |
| EP-2087043-A1 | NEW DS DNA BINDING FLUORESCENT DYES | Roche Diagnostics GmbH (DE) | 2009-08-12 | — | — | EP | disclosed |
| EP-1556055-B1 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE AND THEIR USE IN THERAPY | VIA PHARMACEUTICALS INC (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008052742-A1 | NEW DS DNA BINDING FLUORESCENT DYES | ROCHE DIAGNOSTICS GMBH (DE) | 2008-05-08 | — | — | WO | disclosed |
| US-7250410-B2 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | VIA PHARMACEUTICALS, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060128695-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses | NEURO3D (FR) | 2006-06-15 | — | — | US | disclosed |
| EP-1556055-A2 | USE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE IN THERAPY | NEURO3D (FR) | 2005-07-27 | — | — | EP | disclosed |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | disclosed |
| WO-2004041258-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES | NEURO3D (FR) | 2004-05-21 | — | — | WO | disclosed |
| EP-1392663-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098865-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2002-12-12 | — | — | WO | disclosed |
| US-4212804-A | Process for the preparation of optionally substituted 2,3-indolinediones | SANDOZ, INC. (US) | 1980-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190868-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | PDE10A 1805/4885KDM4E 4441/4885POLB 3631/4885 |
| US-20090275037-A1 | FLUORESCENT DOUBLE STRANDED DNA BINDING DYES | PCNA, DDB1, SSBP1 | PDE10A 4293/4885KDM4E 2261/4885POLB 20/4885 |
| US-20060128695-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses | PDE7A, PDE4A, PDE4B | PDE10A 24/4885KDM4E 2333/4885POLB 1134/4885 |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | PDE7A, PDE3B, PDE3A | PDE10A 14/4885KDM4E 2914/4885POLB 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.